Adaptive Biotechnologies (ADPT) Short term Debt (2023 - 2026)

Adaptive Biotechnologies has disclosed Short term Debt across 4 years of filings, most recently posting $5.8 million for Q1 2026.

• Short term Debt for Q1 2026 came in at $5.8 million, up 188.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 million (up 188.61% YoY), and the FY2025 annual result was $4.6 million, up 436.65% from the prior year.
• Short term Debt came in at $5.8 million for Q1 2026 at Adaptive Biotechnologies, up from $4.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $5.8 million in Q1 2026 to a low of $865000.0 in Q4 2024.
• The 4-year median for Short term Debt is $3.1 million (2025), against an average of $3.1 million.
• Across the five-year window, Short term Debt soared 436.65% in 2025 and soared 188.61% in 2026, its largest moves.
• Adaptive Biotechnologies' Short term Debt stood at $3.2 million in 2023, then plunged by 72.92% to $865000.0 in 2024, then jumped by 436.65% to $4.6 million in 2025, then increased by 25.03% to $5.8 million in 2026.
• The last three Short term Debt figures came in at $5.8 million (Q1 2026), $4.6 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.